ESMO: Merck and AstraZeneca's 5-Year Lynparza Data in Ovarian Cancer and More

AstraZeneca and Merck announced positive five-year follow-up data from the Phase III SOLO-1 trial which demonstrated a long-term progression-free survival (PFS) benefit of Lynparza as a first-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who were in complete or partial response to platinum-based chemotherapy.